Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) hired its associate Kelun Jiaxun for auxiliary promotional services of its drug SKB264, according to a Hong Kong bourse filing Tuesday.
Shares of the drug maker fell nearly 2% in morning trade Wednesday.
The framework will last till the end of 2028, with annual caps of 20 million yuan in service fees payable by Sichuan Kelun-Biotech to Kelun Jiaxun.